CXCR2 and neoplasm: MDSCCXCR2+-mediated suppression of antitumor immunity was just a local phenomenon because inhibition of MDSCCXCR2+ trafficking to the tumor enhanced the potency of PD1 checkpoint blockade, which indicated that combining CXCR2 inhibitors with immune checkpoint inhibitors may become a new combination immunotherapy strategy in cancer.